Immune system
A three-amino-acid peptide from Russian research, studied for calming airway inflammation and supporting aging lungs. Human evidence is still thin.
Start here
Chonluten is an ultrashort peptide of three amino acids (Glu-Asp-Gly), studied for supporting the lining of the airways and calming lung inflammation. Research suggests it works at the gene level in respiratory tissue and dials down inflammatory signaling in lung immune cells. Human evidence is limited, and it is a research compound, not FDA approved.
Chonluten is a peptide extract designed to support cartilage and joint health by providing building blocks and signaling molecules that promote cartilage cell survival and matrix repair.
Chonluten is a bioactive peptide complex from cartilage tissue that contains several amino acid sequences and growth factor mimics (look-alikes of growth signals) able to switch on building-up pathways in chondrocytes (cartilage cells). These peptides interact with integrin receptors (cell-surface anchors) and growth factor receptors on cartilage cells, turning up production of type II collagen, aggrecan and other framework (extracellular matrix) parts, while turning down tissue-degrading enzymes called matrix metalloproteinases (MMPs) through MAPK and Wnt/β-catenin pathways (internal signaling chains).
Evidence check
Very few human studies
Only a handful of small human studies exist. Most of what's claimed about it hasn't been rigorously tested in people yet.
Every numbered marker on this page links to one of the 6 sources at the bottom.
Airway and lung tissue repair
This peptide turns on genes that help your lung lining heal and rebuild, restoring the protective barrier in your airways.
Lung Inflammation Control
Calms down overactive immune signals in your lungs, reducing harmful inflammation that damages breathing tissue over time.
Age-Related Lung Protection
Long-term Russian studies suggest it may help preserve lung function in older adults, though evidence remains limited outside that research.
The most-asked question
The research-reported range is 5–10 mg, once daily. Studies used different doses for different situations — find yours:
Respiratory support, Faster onset
5-10 mg
For the synthetic peptide form, a dose commonly used in research practice given as an injection under the skin. 6
Lung and bronchial support, Maintenance courses
1-2 capsules
The oral capsule plan used in practice for this bronchopulmonary peptide supplement. 6
The ceiling: 10 (as determined by your healthcare provider based on individual response and tolerance)
Reconstitution, in plain words
Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Chonluten:
Chonluten comes in pre-measured doses or forms. Follow the exact dosing instructions on your prescription label. No reconstitution or mixing is typically required for this formulation.
Use Chonluten exactly as prescribed. Each unit contains the labeled amount. Your healthcare provider will determine the appropriate dose based on your individual needs and response.
Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Chonluten's recorded schedule.
Injection sites & technique
Chonluten is taken under the tongue (sublingual) using enteric-coated capsules (capsules with a coating that protects them from stomach acid)—no injection required
Timing
Take Chonluten at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.
Chonluten can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.
Chonluten should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
The honest list
These show up most often. They usually fade as your body adjusts.
Mild redness, slight soreness, or minor swelling at the subcutaneous (under the skin) injection site. Standard for injectable peptide bioregulators.
What to do Rotate injection sites between abdomen, thighs, and upper arms. Apply cold compress if needed. Resolves spontaneously within 24-48 hours.
Slight tiredness during the first days as the lung's immune defenses reset and lung-related genes switch on.
What to do Rest as needed. Usually resolves within 2-3 days. Ensure adequate sleep and hydration.
Mild increase in mucus production or slight changes in respiratory secretions as bronchial epithelial (surface-lining tissue) normalization occurs.
What to do Generally benign — indicates active epithelial (surface-lining tissue) remodeling. Stay hydrated. Should stabilize within several days.
Transient headache during the first few days of treatment, potentially related to immune activation and cytokine (an immune signaling molecule) level adjustment.
What to do Ensure adequate hydration. Standard analgesics if needed. Usually self-limiting.
Worth knowing about, but most people never see these.
Transient mild flu-like response as alveolar macrophage populations activate and TNF tolerance mechanisms engage.
What to do Rest, hydrate, and monitor. Symptoms should resolve within 24-48 hours. If persistent, reduce dose for subsequent administrations.
Rare, but if any of these happen, stop and contact a medical professional.
No serious adverse events, organ toxicity, drug dependence, or severe allergic reactions have been reported across all published clinical studies. No lethal dose established in animal toxicology research.
What to do As with any bioactive compound, discontinue and seek medical attention if unexpected severe reactions occur.
Week by week
Is it right for you?
Chonluten should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
Use with caution—discuss with your healthcare provider.
May be used together under medical guidance.
May be used together under medical guidance.
May be used together under medical guidance.
Generally safe to take alongside Chonluten. Space doses apart if taking oral formulations to ensure optimal absorption.
Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Chonluten is particularly well-suited for individuals focused on respiratory health restoration in aging individuals with declining lung function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Chonluten is particularly well-suited for individuals focused on chronic bronchopulmonary conditions requiring tissue-level regenerative support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Chonluten is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting respiratory and immune function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Chonluten is particularly well-suited for individuals focused on geroprotective therapy for lung tissue preservation in elderly populations. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Chonluten is a cartilage-derived peptide extract used primarily in Russian and Eastern European medicine that lacks FDA approval and rigorous clinical safety data. As a poorly defined mixture of collagen peptides and proteoglycans from cartilage tissue, standardization and batch consistency cannot be guaranteed. Potential risks include allergic reactions to connective tissue proteins, contamination from animal tissues, and unknown immunological effects from proteoglycan components. No formal safety assessments, animal toxicology studies by modern standards, or human Phase 1/2 trials exist. Long-term safety outcomes are completely unstudied.
Evidence is limited to observational clinical use in Russian medical practice over several decades and small open-label studies, mostly published in Russian-language journals. No preclinical (animal or lab studies, not human trials) safety studies, toxicology screening, studies of how the body absorbs and processes it, or randomized controlled trials with formal safety monitoring have been done. The literature consists mostly of descriptive case reports and clinical experience rather than rigorous safety data.
Keeping it good
Store Chonluten in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Once reconstituted, Chonluten should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Not our opinion — the published record
2022
Chonluten peptide and other tissue-specific peptides lower TNF (an inflammation signal) and other inflammation chemicals in immune cells, acting as natural triggers of inflammation tolerance (the immune system learning to calm down) during infections and tissue damage.
Avolio F, Martinotti S, Khavinson VK
2020
Research (2020) on chonluten contributes important scientific knowledge about its biological and pharmacological properties.
Khavinson V, Linkova N, Dyatlova A, et al.
2014
Research (2013) on chonluten contributes important scientific knowledge about its biological and pharmacological properties.
Khavinson VKh, Tendler SM, Vanyushin BF, et al.
2021
Research (2021) on chonluten contributes important scientific knowledge about its biological and pharmacological properties.
Khavinson VK, Popovich IG, Linkova NS, et al.
2003
Thymic and pineal peptides (Thymalin and Epithalamin, short proteins from the thymus and pineal glands) cut deaths in elderly patients by 2-4 fold over 6-8 years while improving heart, immune, and metabolic health.
Khavinson VKh, Morozov VG
2024
Marketed as a peptide supplement. Commonly used in practice at 1-2 capsules once or twice daily with meals; average course 10-30 days, repeated 2-3 times per year. Not approved as a medicine in Western jurisdictions.
If this isn't the right fit
Your questions
Chonluten is a synthetic tripeptide (Glu-Asp-Gly or EDG) classified as T-34 in Khavinson's bioregulator system, specifically designed to target the bronchopulmonary system — the lungs and bronchial tree. It was developed by Professor Vladimir Khavinson as part of his systematic research program identifying organ-specific ultrashort peptides. Chonluten restores respiratory epithelial (surface-lining tissue) function through direct DNA interaction at bronchopulmonary gene promoters, normalizing bronchial mucosa differentiation and reducing pulmonary inflammation.
While Vilon (KE dipeptide) and Thymalin provide systemic (affecting the whole body) immune modulation through thymic T-cell activation, Chonluten specifically targets bronchopulmonary tissue. Its EDG sequence binds to ATTTC DNA sequences found in lung-specific gene promoters, activating respiratory epithelial (surface-lining tissue) differentiation programs rather than general immune pathways. Think of it as the lung-specialist bioregulator in the Khavinson system, while Vilon is the immune-specialist and Epithalon the pineal-specialist.
Chonluten has been studied for its ability to restore the function of the airway lining by bringing Ki-67 and p53 back to normal — markers of cell growth and of programmed cell death (apoptosis (programmed cell death)) that become disrupted in chronic lung disease. By restoring healthy turnover of lining cells, mucus-cell function, and the sweeping of mucus out of the airways, it targets the tissue-level problems behind chronic respiratory conditions. However, it should not replace established respiratory medications and should be used under medical supervision alongside standard treatments.
Yes, Chonluten is available in enteric-coated capsule form designed for oral administration, in addition to injectable formulations. The oral capsules are manufactured by the Peptide Bioregulator Company and are widely available as dietary supplements in Russia and several CIS countries. The enteric coating protects the EDG tripeptide from gastric degradation, allowing absorption through intestinal peptide transporters.
TNF tolerance is a protective adaptation: lung immune cells (alveolar macrophages) stop overreacting to TNF-α (an inflammatory messenger protein) but can still respond to germs. Chonluten is thought to create this state by adjusting phosphorylation (a chemical on/off tag) of MAP kinase (a cell-signaling protein) and by reducing how much cells stick to blood vessel lining in lung tissue. This helps stop the damaging cycle of runaway inflammation seen in cytokine (an immune signaling molecule) storms, chronic obstructive conditions, and age-related lung inflammation — essentially training the lung's immune cells to respond in proportion rather than excessively.
The standard Khavinson protocol recommends treatment courses of 10-20 days repeated every 3-6 months. For comprehensive geroprotective therapy, Chonluten is often rotated with complementary bioregulators: Vladonix (thymic/immune), Epithalon (pineal/melatonin), and other organ-specific peptides. Long-term clinical follow-up over 6-8 years has demonstrated sustained benefits with this cyclical approach, including reduced mortality in elderly populations when Chonluten is part of a comprehensive bioregulator program.
6 sources
Every numbered marker on this page points to one of these. Same sources, same numbering as the Chonluten research profile on Peptide Initiative.
Want the deep science?
Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.
Open the research profileThis guide is education, not medical advice. Chonluten is a research compound that is not FDA-approved for human use. Talk to a clinician before taking anything.
PeptideGeek